Detection of the British mutation of COVID 19 by rapid test available by Newpharm A.E

Greece, like the rest of Europe, is in a worrying situation, due to the release of the most contagious mutation of the new coronavirus, which was initially detected in the United Kingdom and has since spread to twenty-two countries in the European zone. To date, 1,667 samples positive for the British mutant strain B117 have been identified in Greece.

The new strain due to increased transmissibility threatens to increase the number of cases and burden the health systems, warns the WHO and could progressively, as has been done in the UK and increasingly in Denmark, replace the other strains of the virus. circulating in Europe as warned by the director of the European section of the World Health Organization Hans Kluge.

A study in the UK by the Public Health Agency (PHE) in a reference laboratory confirmed the possibility of detecting the B117 "Kent" mutation ("VOC 202012/01") in isolated samples of the COVID-19 mutation from the rapid detection test antigen of the British company Surescreen with sensitivity to high viral loads 97.1% and specificity 99.9%. As a result, the Government of the United Kingdom on 20 February 2020 ordered 20 million dual antigen tests (nasopharyngeal / saliva) from Surescreen to be used as part of an extensive Government Asymptomatic Case Scheme with widespread application in schools and colleges.
The rapid antigen detection test of Covid 19 by the British company Surescreen is available in Greece and Cyprus by Newpharm A.E.

Source: amna.gr